PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.71%
Net income growth at 50-75% of TRVN's 14.41%. Martin Whitman would worry about lagging competitiveness unless expansions are planned.
-1.40%
Negative yoy D&A while TRVN is 27.54%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-49.10%
Both cut yoy SBC, with TRVN at -28.93%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
5.95%
Slight usage while TRVN is negative at -108.42%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.80%
Negative yoy AP while TRVN is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
823.30%
Some yoy usage while TRVN is negative at -108660.87%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
59.87%
Lower 'other non-cash' growth vs. TRVN's 328.66%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-19.06%
Both yoy CFO lines are negative, with TRVN at -19.15%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
96.37%
CapEx growth well above TRVN's 91.81%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.44%
Both yoy lines negative, with TRVN at -30627.79%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
92.69%
We repay more while TRVN is negative at -51.60%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-1494.87%
Negative yoy issuance while TRVN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.